Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance without providing specific guidance. They emphasized a commitment to operational improvements.
Management did not provide specific guidance for future quarters.
The company is focused on improving operational efficiencies.
Natera's earnings report shows a loss per share of $0.54, which may raise concerns among investors about profitability. The stock reacted negatively, dropping 1.99%, likely due to the absence of revenue figures and future guidance. Investors will be looking for signs of improvement in upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019